^
Association details:
| Biomarker: | KRAS A59T |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab
Excerpt:
...a remarkable clinical, radiographic, and CEA biomarker response of a patient with metastatic CRC harboring the A59T missense mutation of KRAS treated for 8 months with panitumumab and a FOLFIRI backbone.
Secondary therapy:
FOLFIRI
